HOME >> MEDICINE >> NEWS
Leading immunosuppressant CellCept significantly extends the lifespan of transplanted kidneys

The analysis showed that after three years treatment with CellCept + tacrolimus, kidney survival was 85.9% versus 80.3% with patients taking sirolimus + tacrolimus immunosuppressants. The outcome was even better for higher risk patients with a kidney survival rate of 74.5% vs 57.5%[i]. The new data were presented at the European Society for Organ Transplantation (ESOT), Geneva, Switzerland. Previous data have shown that CellCept gives a survival benefit when compared to older immunosuppressant drugs and now these new data demonstrate the survival benefit of CellCept combinations over the newer drug regimens.

Kidneys are the most commonly transplanted organs[ii]; for every kidney available there are four people waiting to receive one[iii]. After transplantation, people need to take a combination of immunosuppressant drugs for the rest of their lives to prevent the body rejecting the new organ. By preserving the transplanted organ with CellCept based combinations, doctors can help patients to keep their organs longer, thereby, reducing the burden on the already limited donor pool. One way to achieve this is by choosing combinations based on the low toxicity profile of CellCept, along with reduced doses of the more toxic immunosuppressant drugs to decrease the risk of losing the new kidney.

"We have learnt that the combination of cyclosporine/sirolimus is toxic to the kidney over time and as a result some doctors have switched to a sirolimus/tacrolimus combination, that was perceived to be less toxic," said Prof Herwig-Ulf Meier Kriesche, University of Florida, Gainesville, Fl, USA. "Now we have the data to show that this combination is just as damaging. These data, along with this latest analysis of patients on CellCept combinations, should help us make an evidence-based choice on how best to reduce the risk of toxicity, which we know is associated with some long-term immunosuppressant regimens," he added.


'"/>

Contact: Helen Swift
helen.swift@ketchum.com
+44-20-7611-3637
Ketchum
19-Oct-2005


Page: 1

Related medicine news :

1. Leading prevention researchers meeting in Washington, D.C., May 30-June 1, 2007
2. Leading advocates express support for microbicide research, despite disappointing trial results
3. Leading European experts in magnetic resonance for animals
4. Leading healthcare authorities to address safety and effectiveness
5. Leading international osteoporosis experts to present at worlds largest osteoporosis congress
6. Leading hepatology textbook edited by SLU researchers
7. Leading groups offer NIH direct links to journals to make research access easy for public
8. Leading pediatricians group recommends infants sleep in cribs, not parents beds
9. Leading genomic technology expert to present Dickson Prize Lecture at Pitt
10. Leading experts discuss how to protect premature infants against RSV, a potentially dangerous virus
11. Leading sleep expert at Wake Forest to speak at NIH Consensus Conference

Post Your Comments:
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Affordable ... reimbursement model of all hospitals. Studies show that over ... One simple, easy, low cost tool that great hospitals ... by 20 to 25%. , Their secret? Debriefing - ... anther at the end of an operational event. Debriefing ...
(Date:7/29/2014)... day lead to a more streamlined process for obtaining stem ... of replacement tissue for failing body parts, according to UC ... edition of Cell . , The work builds on ... embryonic state in which they again have the potential to ... this process may soon increase thanks to the scientists, identification ...
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
Breaking Medicine News(10 mins):Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2
(Date:7/29/2014)... Cynosure, Inc. (Nasdaq: CYNO ), which ... for high-volume applications, today reported financial results for the ... results incorporate the acquisition of Palomar Medical Technologies, which ... Second-Quarter 2014 Financial Highlights , ... Non-GAAP net income of $7.1 million, or $0.32 per ...
(Date:7/29/2014)... --   What:   AFFiRiS AG, ... from a Phase I clinical trial of PD01A, a ... disease progression. The Michael J. Fox Foundation supported the ... the impact of the results for patients and the ... 2014         11.00 am ...
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014 /PRNewswire/ ... has amplified with rising incidence rates and the ... of a preventative vaccine. Change is underway as ... interferon regimens towards highly effective, easily-tolerated, interferon-free oral ... Gilead,s mega blockbuster Sovaldi ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
Cached News: